Floatz logo

Degarelix

Prostate Cancer

Bayerprotein_peptidePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
81/ 100
Competitive Position
59/ 100

Competitive context

513 Active assets in the Prostate Cancer cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
VIPIVOTIDE TETRAXETAN
Novartis Pharmaceuticals
Phase 4BB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB

View all 50 →

Same molecule, other indications

Degarelix is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
prostate neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →
cardiovascular disorderDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →